BioHarvest Sciences Inc. is a biotechnology company in Israel and the United States. The company is headquartered in Vancouver, Canada.
| Revenue (TTM) | $35.48M |
| Gross Profit (TTM) | $20.91M |
| EBITDA | $-5.80M |
| Operating Margin | -28.40% |
| Return on Equity | -142.50% |
| Return on Assets | -11.00% |
| Revenue/Share (TTM) | $1.68 |
| Book Value | $0.87 |
| Price-to-Book | 1.79 |
| Price-to-Sales (TTM) | 1.16 |
| EV/Revenue | 1.148 |
| EV/EBITDA | -10.25 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $22.67M |
| Float | $19.32M |
| % Insiders | 14.77% |
| % Institutions | 7.42% |
Volatility is currently contracting
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) plans to pursue a dual listing of its ordinary shares on the Tel Aviv Stock Exchange (TASE), with trading expected to begin on September 8, 2026. The company, which is listed on the Nasdaq Capital Market, expects the TASE listing to provide investors in Israel with access to its shares.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 3, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets. BioHarvest expects its shares to begin trading on the TASE on September 8, 2026.
BioHarvest Sciences Inc. (BHST) Q2 2026 Earnings Call Transcript
BioHarvest Sciences NASDAQ: BHST reported second-quarter 2026 revenue of $8.8 million, up 3.8% from $8.5 million a year earlier, while highlighting its first manufacturing and supply agreement within its contract development and manufacturing organization, or CDMO, business.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported higher second-quarter revenue as the plant-based molecule developer shifted spending toward manufacturing capacity. Revenue for the quarter was $8.8 million, up 3.8% from a year earlier.
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago.
Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth trajectory for CDMO business Reports $8.8 million in Q2 revenue, up 3.8% from Q2 2025 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced results from the second quarter and six months of 2026. Dr. Zaki Rakib, Chief Executive Officer of BioHarvest, stated, "We are extremely pleased to have announced a manufacturing agreement this morning with our UAE-based fragrance customer that secures commitment to produce a fragrance ingredient that is widely regarded as one of the most valuable fragrance raw materials in the world.
Exclusive agreement through 2027 and 2028 is estimated to generate $20-$30 million in revenue Positions BioHarvest in sustainable rare luxury fragrance manufacturing BioHarvest to target additional collaborations in the high-margin rare fragrance space Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - August 11, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced an exclusive manufacturing and supply agreement that secures production of a rare, endangered, fragrance plant cell culture, extending terms of the original Agreement ("the Agreement") with its existing fragrance partner, an undisclosed* customer based in the United Arab Emirates (UAE). This particular scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In addition to presenting, Dr. Rakib will also be participating in one-on-one investor meetings from August 11-12.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the results and provide an update on business operations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BHST and any ticker you trade — then tracks every position and per-strategy win rate.
